European Directorate for the Quality of Medicines & HealthCare | Direction européenne de la qualité du médicament & soins de santé

COUNCIL OF EUROPE
CONSEIL DE L'EUROPE

Certification of Substances Department

Certificate of suitability
No. R0-CEP 2018-302-Rev 00

Name of the substance:
NEWBORN CALF SERUM

Name of holder:
HYCLONE LABORATORIES INC.
925 West 1800 South
United States Am.-84321 Logan, Utah

Site(s) of production:
HYCLONE LABORATORIES INC.
925 West 1800 South
United States Am.-84321 Logan, Utah

After examination of the information provided on the origin of raw material(s) and type of tissue(s) used and on the manufacturing process for this substance on the site(s) of production mentioned above, we certify that the substance **NEWBORN CALF SERUM** meets the criteria described in the current version of the monograph Products with risk of transmitting agents of animal spongiform encephalopathies no. 1483 of the European Pharmacopoeia, current edition including supplements.

- Country of origin of source materials:
  United States of America

- Nature of animal tissues used in manufacture:
  Newborn calf blood

The submitted dossier must be updated after any significant change that may alter the quality, safety or efficacy of the substance, or that may alter the risk of transmitting animal spongiform encephalopathy agents.

Manufacture of the substance shall take place in accordance with a suitable quality assurance system, and in accordance with the dossier submitted.

Failure to comply with these provisions will render this certificate void.

The certificate is valid provided that there has been no deterioration in the TSE status of the country(ies) of origin of the source material.

Address: 7 Allée Kastner, CS 30026
F-67081 Strasbourg (France)
Tel: +33 (0) 3 88 41 30 30 – Fax: +33 (0) 3 88 41 27 71 - e-mail: cep@edqm.eu
Internet: http://www.edqm.eu

This certificate is granted within the framework of the procedure established by the European Pharmacopoeia Commission [Resolution AP-CSP (07) 1] for a period of five years starting from **7 June 2019**. Moreover, it is granted according to the provisions of Directive 2001/83/EC and Directive 2001/82/EC and any subsequent amendment, and the related guidelines.

This certificate has:
lines.

On behalf of the
Director of EDQM

Strasbourg, 7 June 2019

DECLARATION OF ACCESS *(to be filled in by the certificate holder under their own responsibility)*

HyClone Laboratories Inc., as holder of the certificate of suitability

R0-CEP 2018-302-Rev 00 for Newborn Calf Serum

hereby authorises .....
(*name of the pharmaceutical company*)

to use the above-mentioned certificate of suitability in support of their application(s) for the following Marketing Authorisation(s): (*name of product(s) and marketing number(s), if known*)

The holder also certifies that no significant changes to the operations as described in the CEP dossier have been made since the granting of this version of the certificate.

Date and Signature (*of the CEP holder*):

Address: 7 Allée Kastner, CS 30026
F-67081 Strasbourg (France)
Tel: +33 (0) 3 88 41 30 30 – Fax: +33 (0) 3 88 41 27 71 - e-mail: cep@edqm.eu
Internet: http://www.edqm.eu